Genentech, Inc.
NEWS
Genentech is eliminating 474 employees, mostly based out of its South San Francisco facilities. The job cuts are expected to be permanent.
The drug is an investigational monoclonal antibody being developed for tauopathies like progressive supranuclear palsy (PSP) and Alzheimer’s disease.
Roche’s Actemra failed to meet its primary and secondary endpoints in a late-stage study involving hospitalized patients with severe COVID-19 associated pneumonia.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 29, 2020.
It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look.
Shares of Blueprint Medicines are climbing in premarket trading after the company inked a collaboration worth more than $1 billion with Genentech to develop a treatment for cancers driven by oncogenic RET alteration.
Although the trial failed to meet the primary endpoint of PFS, the data for overall survival as a co-primary endpoint is not yet mature. The company plans to continue the trial until the next planned analysis.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 19, 2020.
In a Phase III study, Genentech’s Tecentriq (atezolizumab) in combination with Celgene’s Abraxane followed by chemotherapy demonstrated a statistically significant and clinically meaningful improvement in treating patients with early triple-negative breast cancer.
JOBS
IN THE PRESS